NCCN News

New! Monthly Oncology Tumor Board Series

Starting May 23, 2013, NCCN offered a series of 12 multidisciplinary case-based webinars on a variety of topics, including follicular lymphoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma, triple-negative breast cancer, hormone-sensitive breast cancer, squamous cell carcinoma of the lung, advanced adenocarcinoma of the lung, colorectal cancer, prostate cancer, melanoma, and kidney cancer. Each webinar will be facilitated by 2 faculty members from NCCN Member Institutions to provide multidisciplinary perspectives, including pathology, medical oncology, surgical oncology, and radiation oncology. A different topic will be presented each month for 12 months, beginning May 2013, and continuing education credits will be offered for physicians, nurses, and pharmacists. The Monthly Oncology Tumor Board Series is part of an overall strategy to further engage learners.

The May 23, 2013, Oncology Tumor Board will focus on triple-negative breast cancer. Harold Burstein, MD, PhD, and Jennifer Bellon, MD, Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, will present their multidisciplinary expertise on a range of cases pertaining to triple-negative breast cancer.

Because patients are heterogeneous, patient management should also be individualized. The cases in this webinar are designed to highlight significant clinical decision points concerning treatment selection, toxicity management, and areas of recent change or controversy in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), while reinforcing emerging data from clinical trials. This webinar will allow learners to understand how to apply the standards of care to their practice and health care setting.

Studies show that triple-negative breast cancers (negative for hormone receptors and HER2) have a significantly more aggressive clinical course with increased rates of local recurrence and distant metastases compared with other breast cancer types. Effective targeted breast cancer strategies, including endocrine agents and HER2-directed therapies, are not active against these tumors. In the NCCN Guidelines, systemic chemotherapy is often recommended to prevent a recurrence of disease. Selecting an appropriate therapy is a challenge.1-4

The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions for 97% of malignant cancers. Separate guidelines have been created related to major prevention and screening topics, and a third set focuses on the major supportive care areas. The NCCN Guidelines consist of recommendations based on the best evidence available at the time they are derived. Because new data are published continuously, it is essential that the NCCN Guidelines also be continuously updated and revised to reflect these new data and new clinical information. The goal of the NCCN Guidelines is to help oncologists make major clinical decisions in managing patients by proving ready access to synthesized information. The NCCN Guidelines provide recommendations for appropriate care for most patients; however, individual patient circumstances must be considered when applying these recommendations. This activity series will discuss the specific recommendations in the NCCN Guidelines, and unique patient circumstances that influence how the NCCN Guidelines might be best applied.

For more information, or to register for the event, visit NCCN.org.

References

  • 1

    Dent R, Trudeau M, Pritchard KI et al.. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-4434.

    • Search Google Scholar
    • Export Citation
  • 2

    Montagna E, Bagnardi V, Rotmensz N et al.. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol. 2012;23:324-331.

  • 3

    Dawood S, Broglio K, Esteva FJ et al.. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009;20:621-627.

    • Search Google Scholar
    • Export Citation
  • 4

    Lin NU, Vanderplas A, Hughes ME et al.. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network [abstract]. J Clin Oncol 2009;27(Suppl):Abstract 543.

    • Search Google Scholar
    • Export Citation
  • 1

    Dent R, Trudeau M, Pritchard KI et al.. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-4434.

    • Search Google Scholar
    • Export Citation
  • 2

    Montagna E, Bagnardi V, Rotmensz N et al.. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol. 2012;23:324-331.

  • 3

    Dawood S, Broglio K, Esteva FJ et al.. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009;20:621-627.

    • Search Google Scholar
    • Export Citation
  • 4

    Lin NU, Vanderplas A, Hughes ME et al.. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network [abstract]. J Clin Oncol 2009;27(Suppl):Abstract 543.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 66 11 1
PDF Downloads 15 2 0
EPUB Downloads 0 0 0